Latest filings (excl ownership)
8-K
Cost Associated with Exit or Disposal Activities
12 Apr 24
S-1/A
IPO registration (amended)
2 Apr 24
8-K
Other Events
29 Mar 24
S-1
IPO registration
15 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Mar 24
8-K
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
11 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
Other Events
14 Feb 24
8-K
Departure of Directors or Certain Officers
25 Jan 24
8-K
Other Events
4 Jan 24
S-1
IPO registration
11 Dec 23
8-K
Departure of Directors or Certain Officers
11 Dec 23
8-K
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
11 Dec 23
8-K
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
D
$4.74 mm in equity / options / securities to be acquired, sold $4.74 mm, 1 investor
3 Nov 23
8-K
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting
2 Nov 23
8-K
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
30 Oct 23
424B5
Prospectus supplement for primary offering
30 Oct 23
8-K
Other Events
26 Oct 23
8-K
Other Events
4 Oct 23
UPLOAD
Letter from SEC
6 Sep 23
CORRESP
Correspondence with SEC
28 Aug 23
UPLOAD
Letter from SEC
23 Aug 23
8-K
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR T Cell Therapy
16 Aug 23
8-K
Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
14 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
S-8
Registration of securities for employees
31 Jul 23
8-K
Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences
31 Jul 23
8-K
Entry into a Material Definitive Agreement
20 Jul 23
8-K
Termination of a Material Definitive Agreement
11 Jul 23
8-K
Entry into a Material Definitive Agreement
30 Jun 23
8-K
Departure of Directors or Certain Officers
23 Jun 23
8-K
Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates
22 May 23
8-K
Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
12 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Other Events
20 Apr 23
424B5
Prospectus supplement for primary offering
14 Apr 23
Latest ownership filings
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
3
JAMES B MURPHY
12 Feb 24
4
Change in insider ownership
3 Jan 24
3
Peter Carney
19 Dec 23
4
MICHAEL J ZELEFSKY
7 Jul 23
4
Adam J. Chill
7 Jul 23
4
LINDSAY A MD ROSENWALD
7 Jul 23
4
MICHAEL S WEISS
7 Jul 23
4
Neil Herskowitz
7 Jul 23
4
Manuel MD Litchman
7 Jul 23
3/A
MICHAEL S WEISS
6 Apr 23
3/A
LINDSAY A MD ROSENWALD
6 Apr 23
4
Manuel MD Litchman
3 Apr 23
4
LINDSAY A MD ROSENWALD
3 Apr 23
4
Neil Herskowitz
3 Apr 23
4
MICHAEL J ZELEFSKY
3 Apr 23
4
Adam J. Chill
3 Apr 23
4
MICHAEL S WEISS
3 Apr 23
SC 13D/A
Fortress Biotech, Inc.
13 Jan 23
4
Change in insider ownership
6 Jan 23
SC 13G
BlackRock Inc.
8 Jul 22
3
Eliot M Lurier
7 Jun 22
SC 13G
BlackRock Inc.
4 Feb 22
4
Brian Achenbach
16 Dec 21
4
Manuel MD Litchman
8 Nov 21
4
Brian Achenbach
21 Oct 21
4
LINDSAY A MD ROSENWALD
24 Sep 21
4
Manuel MD Litchman
24 Sep 21
4
Manuel MD Litchman
5 Aug 21
4
MICHAEL J ZELEFSKY
8 Jul 21
4
MICHAEL S WEISS
8 Jul 21
4
LINDSAY A MD ROSENWALD
8 Jul 21
4
Manuel MD Litchman
8 Jul 21
4
Neil Herskowitz
8 Jul 21
4
Adam J. Chill
8 Jul 21
4
Manuel MD Litchman
29 Apr 21
4
Brian Achenbach
16 Apr 21
SC 13G/A
BlackRock Inc.
12 Apr 21
4
Manuel MD Litchman
15 Mar 21
4
LINDSAY A MD ROSENWALD
15 Mar 21